

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5540904

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
PATARA PHARMA, LLC	08/28/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	RESPIVANT SCIENCES LTD.
<b>Street Address:</b>	CLARENDON HOUSE, 2 CHURCH STREET
<b>City:</b>	HAMILTON HM11
<b>State/Country:</b>	BERMUDA
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16277689
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(858)314-1501
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8583141581
<b>Email:</b>	ahrea@mintz.com
<b>Correspondent Name:</b>	MINTZ LEVIN
<b>Address Line 1:</b>	3580 CARMEL MOUNTAIN ROAD, SUITE 300
<b>Address Line 4:</b>	SAN DIEGO, CALIFORNIA 92130
<b>ATTORNEY DOCKET NUMBER:</b>	054186-506C03US
<b>NAME OF SUBMITTER:</b>	MRIDULA P. SHERIN
<b>SIGNATURE:</b>	/Mridula P. Sherin/
<b>DATE SIGNED:</b>	05/24/2019
<b>Total Attachments: 12</b>	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page1.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page2.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page3.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page4.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page5.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page6.tif	
source=Assignment from Parent_ Patara to Respivant Sciences Ltd. _ 054186-506C03US#page7.tif	

source=Assignment from Parent\_Patara to Respivant Sciences Ltd. \_ 054186-506C03US#page8.tif  
source=Assignment from Parent\_Patara to Respivant Sciences Ltd. \_ 054186-506C03US#page9.tif  
source=Assignment from Parent\_Patara to Respivant Sciences Ltd. \_ 054186-506C03US#page10.tif  
source=Assignment from Parent\_Patara to Respivant Sciences Ltd. \_ 054186-506C03US#page11.tif  
source=Assignment from Parent\_Patara to Respivant Sciences Ltd. \_ 054186-506C03US#page12.tif

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5312816

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
PATARA PHARMA, LLC	08/28/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	RESPIVANT SCIENCES LTD.
<b>Street Address:</b>	CLARENDON HOUSE, 2 CHURCH STREET
<b>City:</b>	HAMILTON HM11
<b>State/Country:</b>	BERMUDA
<b>PROPERTY NUMBERS Total: 30</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	61937928
Application Number:	61971709
Application Number:	61978711
Application Number:	62105423
Application Number:	14617130
Application Number:	15117711
Application Number:	14686535
Application Number:	15232731
Application Number:	15621857
Application Number:	15957719
Application Number:	15957724
Application Number:	62105453
Application Number:	14617221
Application Number:	15117712
Application Number:	15232747
Application Number:	62193386
Application Number:	62202552
Application Number:	15750809
Application Number:	62202578
Application Number:	15750811
Application Number:	62381914

PATENT

Property Type	Number
Application Number:	62417898
Application Number:	15887825
Application Number:	15887830
Application Number:	62405587
Application Number:	62417887
Application Number:	62680144
PCT Number:	US2016042437
PCT Number:	US2017049205
PCT Number:	US2017053327

**CORRESPONDENCE DATA**

**Fax Number:** (858)314-1501

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 8583141581

**Email:** ahrea@mintz.com

**Correspondent Name:** MINTZ LEVIN

**Address Line 1:** 3580 CARMEL MOUNTAIN ROAD, SUITE 300

**Address Line 4:** SAN DIEGO, CALIFORNIA 92130

**ATTORNEY DOCKET NUMBER:** 054186\*

**NAME OF SUBMITTER:** MRIDULA P. SHERIN

**SIGNATURE:** /Mridula P. Sherin/

**DATE SIGNED:** 01/07/2019

**Total Attachments: 10**

source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page1.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page2.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page3.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page4.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page5.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page6.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page7.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page8.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page9.tif  
source=Assignment\_Patara\_to\_Respivant\_Sciences\_Ltd#page10.tif

**INTELLECTUAL PROPERTY ASSIGNMENT**

This Intellectual Property Rights Assignment (this "Assignment"), made this 28th day of August, 2018, is by and between Patara Pharma, LLC, a Delaware limited liability company ("Assignor"), and Respivant Sciences Ltd., a company organized under the laws of Bermuda ("Assignee").

WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of the date hereof (as amended, modified or supplemented from time to time, the "Purchase Agreement"), providing, subject to the terms and conditions set forth therein, for the sale, transfer, assignment, conveyance and delivery by Assignor to Assignee of all of Assignor's right, title and interest in and to certain assets of Assignor as set forth in the Purchase Agreement, including Seller Owned Intellectual Property (as such term is defined in the Purchase Agreement);

WHEREAS, the Seller Owned Intellectual Property includes the patents and patent applications and registrations identified on the attached Schedule A (the "Assigned Patents"); and

WHEREAS, in accordance with the Purchase Agreement, Assignee desires to acquire Seller Owned Intellectual Property from Assignor.

NOW, THEREFORE, for good and valuable consideration provided for in the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby irrevocably conveys, transfers and assigns to Assignee, its successors and assigns, all of Assignor's worldwide right, title and interest in and to the Seller Owned Intellectual Property (other than the Patara Trademarks (as such term is defined in the Purchase Agreement) and domain names) ("Assigned Intellectual Property"), as of the Closing (as such term is defined in the Purchase Agreement), including, without limitation the Assigned Patents and all intellectual property rights therein, including all common-law rights therein, rights provided by international conventions and treaties, and all registrations and applications therefor identified on Schedule A. Assignor further assigns to Assignee all of Assignor's rights (i) in and to causes of action and enforcement rights associated with the Assigned Intellectual Property, including, without limitation, all rights to pursue damages, injunctive relief and other remedies for past and future infringement or other violation of the Assigned Intellectual Property and (ii) to apply in any or all countries of the world for trademark and copyright protection for the Assigned Intellectual Property.

From time to time after the Closing, at Assignee's reasonable request and cost, Assignor will execute and deliver such other instruments of sale, transfer, conveyance, and assignment, and provide such materials and information and take such other actions as Assignee may reasonably deem necessary or desirable in order to more effectively transfer, convey and assign to Assignee all of the Assigned Intellectual Property.

Nothing in this Assignment, express or implied, is intended or shall be construed to confer upon, or give to, any person or entity, other than the parties to this Assignment, any rights, remedies, obligations or liabilities.

This Assignment shall bind and inure to Assignee and Assignor and their respective successors and assigns.

This Assignment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

This Assignment shall be exclusively interpreted and governed by the laws of the State of Delaware, without regard to its conflict of law provisions.

The parties acknowledge and agree that the representations, warranties, covenants, agreements and indemnities contained in the Purchase Agreement shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of a conflict between this Assignment and the Purchase Agreement, the terms and conditions of the Purchase Agreement shall take precedence.

[signature pages follow]

IN WITNESS WHEREOF, the undersigned have caused this Intellectual Property Assignment to be executed as of the date first set forth above.

**ASSIGNOR:**

**PATARA PHARMA, LLC,**  
a Delaware limited liability company

By: Bernoulli Pharma Holdings, LLC  
Title: Managing Member

By:   
Name: William M. Gerhart  
Title: Managing Member

Address: 11455 El Camino Real, Suite 460  
San Diego, CA 92130

**ASSIGNEE:**

**RESPIVANT SCIENCES LTD.**

By \_\_\_\_\_  
Name:  
Title:

*[Signature Page to Intellectual Property Assignment]*

IN WITNESS WHEREOF, the undersigned have caused this Intellectual Property Assignment to be executed as of the date first set forth above.

ASSIGNOR:

PATARA PHARMA, LLC


By: \_\_\_\_\_

Name:

Title:

ASSIGNEE:

RESPIVANT SCIENCES LTD.

By: 

Name: *Marianne L. Kuroo*

Title: *Head, Global Transactions & Risk Management*

[Signature Page to Intellectual Property Assignment]



**SCHEDULE A  
Assigned Patents**

<b>Title</b>	<b>Country</b>	<b>App. No.</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent No.</b>	<b>Grant Date</b>
<b>SYSTEMIC FAMILY</b>						
METHOD FOR THE TREATMENT OF MAST CELL DISORDERS WITH MAST CELL STABILIZERS	US	61/937,928	Feb 10, 2014	Expired	N/A	N/A
METHOD FOR THE TREATMENT OF MAST CELL DISORDERS WITH MAST CELL STABILIZERS	US	61/971,709	Mar 28, 2014	Expired	N/A	N/A
METHOD FOR THE TREATMENT OF MAST CELL DISORDERS WITH MAST CELL STABILIZERS	US	61/978,711	Apr 11, 2014	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF SYSTEMATIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	US	62/105,423	Jan 20, 2015	Expired	N/A	N/A
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	PCT	PCT/US15/15029	Feb 9, 2015	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	US	14/617,130	Feb 9, 2015	Abandoned		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	US	15/117,711	Feb 9, 2015	Issued	9,962,363	May 8, 2018

**CONFIDENTIAL**

<b>Title</b>	<b>Country</b>	<b>App. No.</b>	<b>Filing Date</b>	<b>Status</b>	<b>Patent No.</b>	<b>Grant Date</b>
METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	US	14/686,535	Apr 14, 2015	Issued	9,265,749	Feb 23, 2016
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	US	15/232,731	Aug 9, 2016	Issued	9,707,206	Jul 18, 2017
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	US	15/621,857	Jun 13, 2017	Issued	9,968,586	May 15, 2018
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	US	15/957,719	Apr 19, 2018	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	US	15/957,724	Apr 19, 2018	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	AU	2015213678	Feb 9, 2015	Issued	2015213678	Feb 1, 2018
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	AU	2018200429	Feb 9, 2015	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	CA	2,938,994	Feb 9, 2015	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	CN	201580018280.1	Sep 9, 2016	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	EP	15745862.1	Aug 12, 2016	Pending		
MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS	JP	2016-568473	Aug 9, 2016	Pending		

Title	Country	App. No.	Filing Date	Status	Patent No.	Grant Date
<b>LUNG FAMILY</b>						
METHODS FOR THE TREATMENT OF LUNG DISEASES WITH MAST CELL STABILIZERS	US	62/105,453	Jan 20, 2015	Expired	N/A	N/A
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	PCT	PCT/US15/01503 3	Feb 9, 2015	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF LUNG DISEASES WITH MAST CELL STABILIZERS	US	14/617,221	Feb 9, 2015	Abandoned		
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	US	15/117,712	Aug 9, 2016	Pending		
METHODS FOR THE TREATMENT OF LUNG DISEASES WITH MAST CELL STABILIZERS	US	15/232,747	Aug 9, 2016	Pending		
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	AU	2015213681	Aug 9, 2016	Pending		
METHODS FOR THE TREATMENT OF LUNG DISEASES WITH MAST CELL STABILIZERS	CA	2,938,996	Feb 9, 2015	Pending		
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	CN	201580018215.9	Sep 30, 2016	Pending		
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	EP	15746049.4	Aug 12, 2016	Pending		
MAST CELL STABILIZERS FOR LUNG DISEASE TREATMENT	JP	2016-568475	Aug 9, 2016	Pending		

Title	Country	App. No.	Filing Date	Status	Patent No.	Grant Date
<b>COMBINATIONS FAMILY</b>						
COMBINATION THERAPIES FOR THE TREATMENT OF LUNG DISEASES	US	62/193,386	Jul 16, 2015	Expired	N/A	N/A
COMBINATION THERAPIES FOR THE TREATMENT OF LUNG DISEASES	PCT	PCT/US16/04243 7	Jul 15, 2016	Expired	N/A	N/A
<b>ADDITIONAL INDICATIONS FAMILY</b>						
METHODS FOR THE TREATMENT OF MAST CELL RELATED DISORDERS WITH MAST CELL STABILIZERS	US	62/202,552	Aug 7, 2015	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF MAST CELL RELATED DISORDERS WITH MAST CELL STABILIZERS	PCT	PCT/US16/45804	Aug 5, 2016	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF MAST CELL RELATED DISORDERS WITH MAST CELL STABILIZERS	US	15/750,809	Feb 6, 2018	Pending		
METHODS FOR THE TREATMENT OF MAST CELL RELATED DISORDERS WITH MAST CELL STABILIZERS	EP	16751790.3	Aug 5, 2016	Pending		
<b>BIOMARKERS FAMILY</b>						
METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	US	62/202,578	Aug 7, 2015	Expired	N/A	N/A
METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	PCT	PCT/US16/45849	Aug 5, 2016	Pending	N/A	N/A

Title	Country	App. No.	Filing Date	Status	Patent No.	Grant Date
METHODS FOR THE TREATMENT OF SYSTEMIC DISORDERS TREATABLE WITH MAST CELL STABILIZERS, INCLUDING MAST CELL RELATED DISORDERS	US	15/750,811	Feb 2, 2018	Pending		
<b>CHRONIC COUGH/IPF FAMILY</b>						
CROMOLYN COMPOSITIONS FOR TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS	US	62/381,914	Aug 31, 2016	Expired	N/A	N/A
CROMOLYN COMPOSITIONS FOR TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS	US	62/417,898	Nov 4, 2016	Expired	N/A	N/A
CROMOLYN COMPOSITIONS FOR TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS	PCT	PCT/US17/49205	Aug 29, 2017	Pending	N/A	N/A
CROMOLYN COMPOSITIONS FOR TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS	US	15/887,825	Feb 2, 2018	Pending		
CROMOLYN COMPOSITIONS FOR TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS	US	15/887,830	Feb 2, 2018	Pending		
<b>IPF FAMILY</b>						
CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS	US	62/405,587	Oct 7, 2016	Expired	N/A	N/A
CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS	US	62/417,887	Nov 4, 2016	Pending	N/A	N/A

Title	Country	App. No.	Filing Date	Status	Patent No.	Grant Date
CROMOLYN COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROSIS	PCT	PCT/US17/53327	Sep 25, 2017	Pending	N/A	N/A
LIVER FIBROSIS FAMILY						
CROMOLYN COMPOSITIONS FOR TREATMENT OF HEPATIC FIBROSIS	US	62/680,144	Jun 4, 2018	Pending	N/A	N/A